Tomaszewski v. Trevena, Inc.

383 F. Supp. 3d 409
CourtDistrict Court, E.D. Pennsylvania
DecidedMay 29, 2019
DocketCIVIL ACTION NO. 18-4378
StatusPublished
Cited by12 cases

This text of 383 F. Supp. 3d 409 (Tomaszewski v. Trevena, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Tomaszewski v. Trevena, Inc., 383 F. Supp. 3d 409 (E.D. Pa. 2019).

Opinion

Rufe, District Judge.

This is a federal securities class action brought on behalf of investors against Trevena, Inc. and its former executives for violations of §§ 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995 ("PSLRA"), 15 U.S.C. §§ 78j(b) and 78t(a), and Rule 10b-5 promulgated thereunder, *41117 C.F.R. § 240.10b-5.1 As lead plaintiff and lead counsel must be appointed pursuant to 15 U.S.C. § 78u-4, Plaintiffs Huseyin Erenoglu, a group of five individual members2 (collectively, "Trevena Group"), and Lanphie Ping have each moved for such appointment and for approval of their choice of lead counsel.3 Upon consideration of the motions, the responses thereto, and the oral arguments presented at a hearing held on February 20, 2019, the Court determines that Trevena Group shall be appointed as lead plaintiff for the class and approves of Block & Leviton LLP as its choice of lead counsel and Kaufman Coren & Ress, P.C. as liaison counsel, for the following reasons.

I. BACKGROUND4

Trevena is a clinical stage biopharmaceutical company that discovers, develops, and seeks to commercialize therapeutics by utilizing a novel approach to treating moderate to severe acute pain intravenously. Trevena allegedly issued a press release on May 2, 2016, announcing that it had reached a general agreement with the FDA on key elements of its clinical development program for one of its products, Olinvo (oliceridine). Based on those statements and omissions as to the strength of the program, the design of its Phase III trial, and its prospects for obtaining FDA approval, the price of Trevena's stock began to increase. On October 9, 2018, however, two days before the FDA would meet with Trevena to determine whether Olinvo would be granted approval, the FDA publicized a briefing document which contained minutes from its 2016 meeting with Trevena that it previously criticized the design of the Phase III trial and that the FDA's Advisory Committee was recommending rejection of Olinvo's new drug application. As a result, the price of Trevena's stock dropped 64% by the time the market closed on October 9. Plaintiffs are comprised of investors who purchased Trevena common stock between May 2, 2016 and October 8, 2018 (the "Class Period").

The Court has previously consolidated the three separate lawsuits against Trevena and its former executives, and now must decide whether Erenoglu, Trevena Group, or Ping will serve as lead plaintiff. A hearing was held on February 20, 2019, after which the Court required Erenoglu to produce his trade confirmations from the Class Period to the Court and to the other Moving Plaintiffs, and permitted further briefing upon receipt of the trade confirmations.5

II. PROCEDURAL REQUIREMENTS

The PSLRA requires that within 20 days of filing a complaint, the plaintiff must "cause to be published, in a widely circulated national business-oriented publication or wire service," notice to members of the purported class as to "the pendency of the action, the claims asserted therein, and the purported class period."6 Within 60 days of the date on which the notice is *412published, "any member of the purported class may move the court to serve as lead plaintiff of the purported class."7

On October 11, 2018, one day after the Complaint was filed, a notice of the pendency of this action was published on PR Newswire , a national business-oriented newswire service.8 On December 10, 2018, 60 days after the notification release, Erenoglu, Trevena Group, and Ping each filed timely motions to serve as lead plaintiff, and for appointment of lead counsel for the class.9

III. LEGAL STANDARD

Under the PSLRA, the court must appoint a lead plaintiff "as soon as practicable" after a class action securities lawsuit has been consolidated.10 The presumptive lead plaintiff is the investor with the largest financial interest in the outcome of the action, as long as that investor satisfies the following Federal Rule of Civil Procedure 23 requirements: (1) the claims must be typical of and share common questions of law with the claims of the absent class members, and (2) the investor must adequately represent the interests of the entire class.11

The presumption "may be rebutted only upon proof by a member of the purported plaintiff class that the presumptively most adequate plaintiff" either: (1) "will not fairly and adequately protect the interests of the class"; or (2) "is subject to unique defenses that render such plaintiff incapable of adequately representing the class."12 If the court finds, for any reason, that the movant with the largest loss cannot make a threshold showing of typicality and adequacy, the court must explain its reasons, disqualify that movant, and "then identify the movant with the next largest loss, consider whether that movant satisfies Rule 23's requirements, and repeat this process until a presumptive lead plaintiff is identified."13

IV. DISCUSSION

A. Largest Financial Loss

The three relevant factors when analyzing the largest financial interest are: (1) the number of shares purchased during the class period; (2) the total net funds expended by the plaintiffs during the class period; and (3) the approximate losses suffered by the plaintiffs.14 The third factor-the approximate losses suffered-has been considered by courts within this Circuit to be the most significant in the context of *413securities litigation.15

Erenoglu alleges that he suffered the greatest financial loss of $ 552,075.43.16 Both Trevena Group and Ping have contested this calculation in their briefs and during the hearing. Erenoglu was ordered to produce his trade confirmations,17 which revealed that Erenoglu had overstated his total losses by $ 518.61. Nevertheless, for purposes of the largest financial interest, Erenoglu still retains the largest financial interest of the Moving Plaintiffs in this case,18 as Trevena Group's five members show aggregated total losses of approximately $ 485,972.97,19 and Lanphie Ping lost $ 205,654.53.20

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
383 F. Supp. 3d 409, Counsel Stack Legal Research, https://law.counselstack.com/opinion/tomaszewski-v-trevena-inc-paed-2019.